RIPK3 and non-small cell lung carcinoma: Phosphorylation of receptor-interacting protein kinase-3 (RIPK3) and phosphorylation of mixed-lineage kinase domain-like protein (MLKL) in gefitinib treated NSCLC cells overexpressing ID1, results in the disruption of the plasma membrane [28].